At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 229 enrolled
Drug / intervention
ARO-APOC3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
In Brief
A Phase 2 clinical trial evaluating ARO-APOC3 and Placebo for Severe Hypertriglyceridemia. Completed, enrolled 229 participants across 74 sites in 8 countries.
Detailed Summary
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Hypertriglyceridemia
CountriesAustralia, Canada, Germany, Hungary, Netherlands, New Zealand, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartMay 2021
Primary CompletionMar 2023
Study CompletionAug 2023
TodayJul 2026
First PostedJan 22, 2021
Enrollment StartMay 31, 2021
Primary CompletionMar 9, 2023
Study CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.4 years ago
Interventions
ARO-APOC3drug
2 doses of ARO-APOC3 by subcutaneous (sc) injection
Placebodrug
calculated volume to match active treatment by sc injection